Hjem › Leukemi › Texas › Houston
Kliniske studier for Leukemi i Houston, TX
28 studier for Leukemi søker deltakere på steder i og rundt Houston (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservasjonsstudie
- Texas Children's Hospital, Houston
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RekruttererFase 3
- Quetzal Site 6, Houston
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RekruttererFase 2
- M D Anderson Cancer Center, Houston
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
RekruttererFase 1
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RekruttererFase 2
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RekruttererFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RekruttererFase 2
- MD Anderson Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
RekruttererFase 3
- Research Site, Houston
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
RekruttererFase 1
- Texas Children's Hospital, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RekruttererFase 1/2
- MD Anderson Cancer Center, Houston
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RekruttererFase 3
- University of Texas, Houston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruttererFase 1
- MD Anderson Cancer Center, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RekruttererFase 2
- Baylor Texas Children's Hospital, Houston
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
RekruttererFase 1/2
- Research Site, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RekruttererFase 2
- University of Texas MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
RekruttererFase 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Revumenib and Mezigdomide in People With Leukemia
RekruttererFase 1/2
- MD Anderson Cancer Center (Data Collection Only), Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
RekruttererFase 1/2
- Dren Investigational Site, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
RekruttererObservasjonsstudie
- M D Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
RekruttererObservasjonsstudie
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RekruttererFase 2
- M D Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekruttererFase 2/3
- MD Anderson Cancer Center, Houston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekruttererFase 1
- MD Anderson Cancer Center, Houston
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruttererFase 1
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Houston
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RekruttererFase 1
- The University of Texas M.D. Anderson Cancer Center, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RekruttererFase 1
- MD Anderson Cancer Center, Houston
Leukemi-studier i andre byer
- Boston, MA25 studier
- New York City, NY19 studier
- Los Angeles, CA16 studier
- Chicago, IL16 studier
- Durham, NC13 studier
- Baldwin Park, CA12 studier
- Columbus, OH12 studier
- Nashville, TN12 studier
- Philadelphia, PA12 studier
- Milwaukee, WI11 studier
- Atlanta, GA11 studier
- Seattle, WA11 studier
Andre studier i Houston
- Ikke-småcellet lungekreft145 studier
- Brystkreft126 studier
- Kreft (alle typer)121 studier
- Metastatisk kreft104 studier
- Kolorektal kreft102 studier
- Eggstokkreft89 studier
- Akut myelogen leukemi85 studier
- Lungekreft78 studier
- Prostatakreft76 studier
- Endometriekreft68 studier
- Pankreaskreft61 studier
- Melanom59 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.